Targeted therapy in head and neck cancer

Lisa Licitra, Cristiana Bergamini, Aurora Mirabile, Roberta Granata

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: Results of clinical studies on targeted cancer therapies are rapidly accumulating. This is also true in the field of head and neck cancer (HNC). Due to the unique multidisciplinary needs of the disease, it is of paramount importance that physicians who treat HNC are aware of the evolving changes that research is offering. RECENT FINDINGS: Many targeted agents directed at inhibiting epithelial growth factor receptors (EGFRs) are under investigation in both curable loco-regional advanced disease in combination with standard treatments and in the recurrent metastatic setting. Human papilloma virus (HPV)-positive tumors present a distinct biological profile. Consequently, the role of targeted agents in this specific setting still needs to be refined. Herein we will briefly review the results of the most recent studies on targeted agents. Cetuximab and other monoclonal antibodies (panitumumab, zalotumumab and nimotumumab) have been already investigated in phase III studies; and some results are now available. Small molecules inhibiting EGFR have still to prove their efficacy. Other agents such as vascular endothelial cell growth factor receptor, vascular endoinsulin-like growth factor 1 receptor, MET, PI3KA and mammalian target of rapamycin inhibitor are in development. SUMMARY: At present treatment options in HNC are changing and include targeted agents with demonstrated efficacy. A better selection based on biological factors of patients who are potentially responsive to such targeted agents is being actively pursued.

Original languageEnglish
Pages (from-to)132-137
Number of pages6
JournalCurrent Opinion in Otolaryngology and Head and Neck Surgery
Volume19
Issue number2
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Growth Factor Receptors
Head and Neck Neoplasms
Papillomaviridae
Vascular Endothelial Growth Factor Receptor
Biological Factors
Sirolimus
Blood Vessels
Neoplasms
Therapeutics
Monoclonal Antibodies
Physicians
Research

Keywords

  • biological update
  • clinical update
  • head neck cancer
  • target therapy

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery

Cite this

Targeted therapy in head and neck cancer. / Licitra, Lisa; Bergamini, Cristiana; Mirabile, Aurora; Granata, Roberta.

In: Current Opinion in Otolaryngology and Head and Neck Surgery, Vol. 19, No. 2, 04.2011, p. 132-137.

Research output: Contribution to journalArticle

@article{513ffaaacac04b9c93c046f651dc3931,
title = "Targeted therapy in head and neck cancer",
abstract = "PURPOSE OF REVIEW: Results of clinical studies on targeted cancer therapies are rapidly accumulating. This is also true in the field of head and neck cancer (HNC). Due to the unique multidisciplinary needs of the disease, it is of paramount importance that physicians who treat HNC are aware of the evolving changes that research is offering. RECENT FINDINGS: Many targeted agents directed at inhibiting epithelial growth factor receptors (EGFRs) are under investigation in both curable loco-regional advanced disease in combination with standard treatments and in the recurrent metastatic setting. Human papilloma virus (HPV)-positive tumors present a distinct biological profile. Consequently, the role of targeted agents in this specific setting still needs to be refined. Herein we will briefly review the results of the most recent studies on targeted agents. Cetuximab and other monoclonal antibodies (panitumumab, zalotumumab and nimotumumab) have been already investigated in phase III studies; and some results are now available. Small molecules inhibiting EGFR have still to prove their efficacy. Other agents such as vascular endothelial cell growth factor receptor, vascular endoinsulin-like growth factor 1 receptor, MET, PI3KA and mammalian target of rapamycin inhibitor are in development. SUMMARY: At present treatment options in HNC are changing and include targeted agents with demonstrated efficacy. A better selection based on biological factors of patients who are potentially responsive to such targeted agents is being actively pursued.",
keywords = "biological update, clinical update, head neck cancer, target therapy",
author = "Lisa Licitra and Cristiana Bergamini and Aurora Mirabile and Roberta Granata",
year = "2011",
month = "4",
doi = "10.1097/MOO.0b013e328344b668",
language = "English",
volume = "19",
pages = "132--137",
journal = "Current Opinion in Otolaryngology and Head and Neck Surgery",
issn = "1068-9508",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Targeted therapy in head and neck cancer

AU - Licitra, Lisa

AU - Bergamini, Cristiana

AU - Mirabile, Aurora

AU - Granata, Roberta

PY - 2011/4

Y1 - 2011/4

N2 - PURPOSE OF REVIEW: Results of clinical studies on targeted cancer therapies are rapidly accumulating. This is also true in the field of head and neck cancer (HNC). Due to the unique multidisciplinary needs of the disease, it is of paramount importance that physicians who treat HNC are aware of the evolving changes that research is offering. RECENT FINDINGS: Many targeted agents directed at inhibiting epithelial growth factor receptors (EGFRs) are under investigation in both curable loco-regional advanced disease in combination with standard treatments and in the recurrent metastatic setting. Human papilloma virus (HPV)-positive tumors present a distinct biological profile. Consequently, the role of targeted agents in this specific setting still needs to be refined. Herein we will briefly review the results of the most recent studies on targeted agents. Cetuximab and other monoclonal antibodies (panitumumab, zalotumumab and nimotumumab) have been already investigated in phase III studies; and some results are now available. Small molecules inhibiting EGFR have still to prove their efficacy. Other agents such as vascular endothelial cell growth factor receptor, vascular endoinsulin-like growth factor 1 receptor, MET, PI3KA and mammalian target of rapamycin inhibitor are in development. SUMMARY: At present treatment options in HNC are changing and include targeted agents with demonstrated efficacy. A better selection based on biological factors of patients who are potentially responsive to such targeted agents is being actively pursued.

AB - PURPOSE OF REVIEW: Results of clinical studies on targeted cancer therapies are rapidly accumulating. This is also true in the field of head and neck cancer (HNC). Due to the unique multidisciplinary needs of the disease, it is of paramount importance that physicians who treat HNC are aware of the evolving changes that research is offering. RECENT FINDINGS: Many targeted agents directed at inhibiting epithelial growth factor receptors (EGFRs) are under investigation in both curable loco-regional advanced disease in combination with standard treatments and in the recurrent metastatic setting. Human papilloma virus (HPV)-positive tumors present a distinct biological profile. Consequently, the role of targeted agents in this specific setting still needs to be refined. Herein we will briefly review the results of the most recent studies on targeted agents. Cetuximab and other monoclonal antibodies (panitumumab, zalotumumab and nimotumumab) have been already investigated in phase III studies; and some results are now available. Small molecules inhibiting EGFR have still to prove their efficacy. Other agents such as vascular endothelial cell growth factor receptor, vascular endoinsulin-like growth factor 1 receptor, MET, PI3KA and mammalian target of rapamycin inhibitor are in development. SUMMARY: At present treatment options in HNC are changing and include targeted agents with demonstrated efficacy. A better selection based on biological factors of patients who are potentially responsive to such targeted agents is being actively pursued.

KW - biological update

KW - clinical update

KW - head neck cancer

KW - target therapy

UR - http://www.scopus.com/inward/record.url?scp=79953863840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953863840&partnerID=8YFLogxK

U2 - 10.1097/MOO.0b013e328344b668

DO - 10.1097/MOO.0b013e328344b668

M3 - Article

C2 - 21372717

AN - SCOPUS:79953863840

VL - 19

SP - 132

EP - 137

JO - Current Opinion in Otolaryngology and Head and Neck Surgery

JF - Current Opinion in Otolaryngology and Head and Neck Surgery

SN - 1068-9508

IS - 2

ER -